| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Torticollis | 45 | 2023 | 69 | 10.330 |
Why?
|
| Parkinson Disease | 74 | 2023 | 1184 | 5.340 |
Why?
|
| Botulinum Toxins, Type A | 25 | 2023 | 35 | 5.200 |
Why?
|
| Dystonia | 21 | 2023 | 54 | 3.730 |
Why?
|
| Botulinum Toxins | 20 | 2018 | 32 | 3.560 |
Why?
|
| Dystonic Disorders | 18 | 2023 | 30 | 3.290 |
Why?
|
| Neuromuscular Agents | 14 | 2023 | 20 | 3.060 |
Why?
|
| Sleep Wake Disorders | 9 | 2014 | 148 | 1.930 |
Why?
|
| Humans | 170 | 2023 | 29883 | 1.760 |
Why?
|
| Restless Legs Syndrome | 8 | 2015 | 11 | 1.730 |
Why?
|
| Severity of Illness Index | 29 | 2019 | 1126 | 1.720 |
Why?
|
| Antiparkinson Agents | 13 | 2021 | 133 | 1.640 |
Why?
|
| Dopamine Agonists | 8 | 2021 | 47 | 1.610 |
Why?
|
| Middle Aged | 89 | 2021 | 9959 | 1.360 |
Why?
|
| Exercise Therapy | 8 | 2018 | 113 | 1.310 |
Why?
|
| Female | 96 | 2023 | 16472 | 1.210 |
Why?
|
| Tardive Dyskinesia | 4 | 2020 | 4 | 1.190 |
Why?
|
| Male | 96 | 2023 | 15870 | 1.180 |
Why?
|
| Levodopa | 9 | 2021 | 142 | 1.050 |
Why?
|
| Antipsychotic Agents | 4 | 2020 | 83 | 1.020 |
Why?
|
| Acetylcholine Release Inhibitors | 4 | 2018 | 4 | 1.010 |
Why?
|
| Tetrabenazine | 3 | 2019 | 3 | 1.000 |
Why?
|
| Valine | 3 | 2019 | 11 | 1.000 |
Why?
|
| Aged | 67 | 2020 | 9620 | 0.960 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 297 | 0.960 |
Why?
|
| Adult | 60 | 2023 | 8774 | 0.950 |
Why?
|
| Blepharospasm | 7 | 2022 | 8 | 0.940 |
Why?
|
| Muscle Weakness | 6 | 2016 | 34 | 0.870 |
Why?
|
| Apomorphine | 2 | 2021 | 37 | 0.850 |
Why?
|
| Tremor | 10 | 2023 | 143 | 0.840 |
Why?
|
| Carbidopa | 4 | 2021 | 45 | 0.840 |
Why?
|
| Neurologic Examination | 7 | 2016 | 154 | 0.830 |
Why?
|
| Vesicular Monoamine Transport Proteins | 2 | 2019 | 4 | 0.830 |
Why?
|
| Treatment Outcome | 25 | 2023 | 3558 | 0.810 |
Why?
|
| Dopamine Agents | 3 | 2015 | 40 | 0.800 |
Why?
|
| Anti-Dyskinesia Agents | 4 | 2013 | 6 | 0.790 |
Why?
|
| Movement Disorders | 6 | 2023 | 148 | 0.790 |
Why?
|
| Double-Blind Method | 22 | 2021 | 522 | 0.770 |
Why?
|
| Neck | 4 | 2023 | 34 | 0.750 |
Why?
|
| Ubiquitin-Protein Ligases | 8 | 2014 | 39 | 0.730 |
Why?
|
| Muscle Rigidity | 2 | 2018 | 26 | 0.700 |
Why?
|
| Multiple System Atrophy | 5 | 2022 | 42 | 0.700 |
Why?
|
| Dopamine Antagonists | 2 | 2019 | 14 | 0.690 |
Why?
|
| Dyskinesia, Drug-Induced | 2 | 2019 | 55 | 0.680 |
Why?
|
| Nervous System Diseases | 3 | 2015 | 150 | 0.670 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2019 | 8 | 0.670 |
Why?
|
| Quality of Life | 11 | 2021 | 677 | 0.640 |
Why?
|
| Catatonia | 1 | 2018 | 1 | 0.640 |
Why?
|
| Encephalomyelitis | 1 | 2018 | 1 | 0.640 |
Why?
|
| Parkinsonian Disorders | 5 | 2022 | 222 | 0.640 |
Why?
|
| Myoclonus | 1 | 2018 | 34 | 0.630 |
Why?
|
| Masticatory Muscles | 1 | 2018 | 1 | 0.630 |
Why?
|
| Motor Activity | 3 | 2015 | 372 | 0.610 |
Why?
|
| Disorders of Excessive Somnolence | 5 | 2021 | 15 | 0.600 |
Why?
|
| Head | 3 | 2020 | 23 | 0.600 |
Why?
|
| Supranuclear Palsy, Progressive | 4 | 2022 | 44 | 0.600 |
Why?
|
| Telemedicine | 1 | 2019 | 99 | 0.590 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2018 | 106 | 0.560 |
Why?
|
| Sleep | 5 | 2019 | 319 | 0.510 |
Why?
|
| Anticonvulsants | 2 | 2014 | 111 | 0.490 |
Why?
|
| Neck Muscles | 3 | 2005 | 13 | 0.490 |
Why?
|
| Reproducibility of Results | 10 | 2019 | 803 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 194 | 0.460 |
Why?
|
| Electromyography | 12 | 2016 | 79 | 0.460 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2018 | 446 | 0.460 |
Why?
|
| Movement | 9 | 2019 | 146 | 0.440 |
Why?
|
| Essential Tremor | 6 | 2013 | 17 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2016 | 348 | 0.370 |
Why?
|
| Mutation | 7 | 2016 | 399 | 0.360 |
Why?
|
| Video Recording | 6 | 2022 | 47 | 0.340 |
Why?
|
| Machine Learning | 2 | 2019 | 54 | 0.330 |
Why?
|
| Drug Combinations | 2 | 2021 | 82 | 0.330 |
Why?
|
| Sleep Stages | 2 | 2006 | 34 | 0.320 |
Why?
|
| Basal Ganglia | 4 | 2014 | 30 | 0.320 |
Why?
|
| Prospective Studies | 13 | 2023 | 1837 | 0.320 |
Why?
|
| Registries | 5 | 2017 | 191 | 0.310 |
Why?
|
| Muscle Contraction | 6 | 2008 | 83 | 0.310 |
Why?
|
| Age of Onset | 9 | 2018 | 110 | 0.310 |
Why?
|
| Deglutition Disorders | 4 | 2014 | 45 | 0.300 |
Why?
|
| Cognition Disorders | 7 | 2015 | 1032 | 0.290 |
Why?
|
| Pergolide | 2 | 2005 | 14 | 0.290 |
Why?
|
| Resistance Training | 3 | 2017 | 8 | 0.280 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2019 | 97 | 0.280 |
Why?
|
| Muscle, Skeletal | 6 | 2008 | 354 | 0.280 |
Why?
|
| Time Factors | 11 | 2015 | 1642 | 0.280 |
Why?
|
| Brain | 6 | 2019 | 1727 | 0.270 |
Why?
|
| Telephone | 1 | 2006 | 27 | 0.270 |
Why?
|
| Hallucinations | 4 | 2007 | 87 | 0.260 |
Why?
|
| Hand Strength | 5 | 2013 | 60 | 0.260 |
Why?
|
| United States | 9 | 2019 | 2345 | 0.260 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2005 | 5 | 0.250 |
Why?
|
| Muscle Spasticity | 3 | 2016 | 16 | 0.250 |
Why?
|
| Videotape Recording | 3 | 2003 | 46 | 0.250 |
Why?
|
| Psychotic Disorders | 3 | 2019 | 45 | 0.250 |
Why?
|
| Sleep, REM | 3 | 2003 | 18 | 0.250 |
Why?
|
| Physical Examination | 2 | 2023 | 117 | 0.240 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 970 | 0.240 |
Why?
|
| Drug Administration Schedule | 5 | 2014 | 232 | 0.240 |
Why?
|
| History, 20th Century | 2 | 2017 | 91 | 0.240 |
Why?
|
| Dyskinesias | 4 | 2008 | 35 | 0.240 |
Why?
|
| Clinical Trials as Topic | 7 | 2014 | 337 | 0.230 |
Why?
|
| Follow-Up Studies | 12 | 2016 | 1856 | 0.230 |
Why?
|
| Cerebral Palsy | 1 | 2023 | 9 | 0.220 |
Why?
|
| Autistic Disorder | 1 | 2023 | 46 | 0.220 |
Why?
|
| Neurotoxins | 2 | 2016 | 19 | 0.220 |
Why?
|
| Young Adult | 6 | 2023 | 1968 | 0.220 |
Why?
|
| Psychomotor Performance | 5 | 2014 | 220 | 0.210 |
Why?
|
| Progesterone | 2 | 2001 | 36 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 455 | 0.210 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 558 | 0.210 |
Why?
|
| Estrogens | 2 | 2001 | 37 | 0.210 |
Why?
|
| Phenotype | 5 | 2021 | 363 | 0.210 |
Why?
|
| Heterozygote | 6 | 2014 | 103 | 0.210 |
Why?
|
| Exercise | 2 | 2017 | 474 | 0.210 |
Why?
|
| Animals | 8 | 2016 | 4620 | 0.210 |
Why?
|
| Injections, Intramuscular | 3 | 2017 | 12 | 0.210 |
Why?
|
| Surveys and Questionnaires | 8 | 2018 | 1188 | 0.210 |
Why?
|
| Benzothiazoles | 2 | 2013 | 20 | 0.210 |
Why?
|
| Feasibility Studies | 2 | 2020 | 230 | 0.200 |
Why?
|
| Automobile Driving | 1 | 2002 | 12 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2014 | 1247 | 0.200 |
Why?
|
| Tics | 1 | 2001 | 11 | 0.200 |
Why?
|
| Phenylalanine | 1 | 2021 | 6 | 0.200 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 12 | 0.200 |
Why?
|
| Symptom Assessment | 1 | 2021 | 21 | 0.200 |
Why?
|
| Carbamates | 1 | 2021 | 12 | 0.200 |
Why?
|
| Tourette Syndrome | 1 | 2001 | 46 | 0.200 |
Why?
|
| Iron | 2 | 2015 | 21 | 0.200 |
Why?
|
| Glucosylceramidase | 2 | 2012 | 26 | 0.190 |
Why?
|
| Polysomnography | 3 | 2010 | 93 | 0.190 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 1 | 2020 | 3 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2022 | 3325 | 0.190 |
Why?
|
| Martial Arts | 1 | 2020 | 5 | 0.190 |
Why?
|
| Neuropsychological Tests | 8 | 2015 | 1270 | 0.190 |
Why?
|
| Internationality | 1 | 2020 | 24 | 0.190 |
Why?
|
| Adolescent | 5 | 2023 | 2335 | 0.190 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2017 | 144 | 0.190 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 399 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 221 | 0.180 |
Why?
|
| Longitudinal Studies | 6 | 2018 | 1462 | 0.180 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 13 | 0.180 |
Why?
|
| Neurites | 1 | 2019 | 12 | 0.170 |
Why?
|
| Analysis of Variance | 9 | 2013 | 327 | 0.170 |
Why?
|
| Mood Disorders | 1 | 2019 | 31 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2019 | 77 | 0.170 |
Why?
|
| Deep Brain Stimulation | 2 | 2011 | 74 | 0.170 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 48 | 0.170 |
Why?
|
| Cerebellum | 3 | 2014 | 56 | 0.160 |
Why?
|
| Central Nervous System Depressants | 1 | 2018 | 24 | 0.160 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2018 | 1 | 0.160 |
Why?
|
| Glutamate Decarboxylase | 1 | 2018 | 4 | 0.160 |
Why?
|
| Isometric Contraction | 5 | 2006 | 15 | 0.160 |
Why?
|
| Wounds and Injuries | 1 | 1998 | 44 | 0.160 |
Why?
|
| Syndrome | 1 | 2018 | 89 | 0.160 |
Why?
|
| Ataxia | 1 | 2019 | 79 | 0.160 |
Why?
|
| Biomechanical Phenomena | 7 | 2023 | 680 | 0.160 |
Why?
|
| High-Intensity Interval Training | 1 | 2018 | 2 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 123 | 0.160 |
Why?
|
| Violence | 1 | 1998 | 39 | 0.160 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 4932 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2020 | 507 | 0.150 |
Why?
|
| Age Factors | 5 | 2019 | 854 | 0.150 |
Why?
|
| Hypokinesia | 2 | 2016 | 27 | 0.150 |
Why?
|
| DNA Mutational Analysis | 3 | 2012 | 57 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 703 | 0.150 |
Why?
|
| Autoantibodies | 1 | 2018 | 105 | 0.150 |
Why?
|
| Postural Balance | 3 | 2015 | 122 | 0.150 |
Why?
|
| Intellectual Disability | 1 | 2018 | 48 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2017 | 37 | 0.150 |
Why?
|
| Fatigue | 2 | 2008 | 63 | 0.150 |
Why?
|
| Task Performance and Analysis | 1 | 1997 | 55 | 0.150 |
Why?
|
| Pain | 3 | 2021 | 397 | 0.150 |
Why?
|
| Ethanol | 1 | 2018 | 135 | 0.150 |
Why?
|
| Patient Selection | 1 | 2018 | 235 | 0.140 |
Why?
|
| Exercise Test | 1 | 2018 | 124 | 0.140 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2007 | 5 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 104 | 0.140 |
Why?
|
| Posture | 3 | 2022 | 79 | 0.140 |
Why?
|
| Neck Pain | 1 | 2017 | 32 | 0.140 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2007 | 32 | 0.140 |
Why?
|
| Genotype | 6 | 2014 | 407 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2016 | 3 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 77 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2015 | 332 | 0.140 |
Why?
|
| Muscle Strength | 2 | 2016 | 129 | 0.140 |
Why?
|
| Anxiety | 3 | 2023 | 157 | 0.140 |
Why?
|
| Headache | 1 | 2016 | 43 | 0.130 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 67 | 0.130 |
Why?
|
| Naloxone | 1 | 2015 | 12 | 0.130 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2016 | 47 | 0.130 |
Why?
|
| Oxycodone | 1 | 2015 | 6 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2015 | 9 | 0.130 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 60 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 86 | 0.130 |
Why?
|
| Single-Blind Method | 4 | 2016 | 120 | 0.130 |
Why?
|
| Huntington Disease | 1 | 2016 | 61 | 0.130 |
Why?
|
| Computer Security | 1 | 2015 | 8 | 0.130 |
Why?
|
| Physical Endurance | 1 | 2015 | 12 | 0.130 |
Why?
|
| Europe | 1 | 2015 | 85 | 0.120 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2014 | 23 | 0.120 |
Why?
|
| Genetic Testing | 5 | 2014 | 64 | 0.120 |
Why?
|
| Sensorimotor Cortex | 1 | 2014 | 1 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2021 | 644 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2020 | 1954 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 46 | 0.120 |
Why?
|
| ROC Curve | 3 | 2013 | 140 | 0.120 |
Why?
|
| Depression | 3 | 2018 | 472 | 0.120 |
Why?
|
| Observer Variation | 4 | 2005 | 119 | 0.120 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 32 | 0.120 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 18 | 0.120 |
Why?
|
| Hand | 4 | 2008 | 46 | 0.110 |
Why?
|
| Health Planning Guidelines | 1 | 2013 | 11 | 0.110 |
Why?
|
| Physical Therapy Modalities | 1 | 1994 | 81 | 0.110 |
Why?
|
| Globus Pallidus | 2 | 2013 | 31 | 0.110 |
Why?
|
| Psychometrics | 3 | 2013 | 264 | 0.110 |
Why?
|
| Muscle Stretching Exercises | 1 | 2012 | 4 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2013 | 79 | 0.110 |
Why?
|
| Tai Ji | 1 | 2012 | 10 | 0.100 |
Why?
|
| Genetic Carrier Screening | 1 | 2012 | 12 | 0.100 |
Why?
|
| Research Design | 1 | 2014 | 215 | 0.100 |
Why?
|
| Menstrual Cycle | 2 | 2001 | 34 | 0.100 |
Why?
|
| Mandibular Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Smell | 1 | 2010 | 18 | 0.090 |
Why?
|
| Circadian Rhythm | 2 | 2005 | 283 | 0.090 |
Why?
|
| Genetic Counseling | 1 | 2010 | 5 | 0.090 |
Why?
|
| Sex Factors | 2 | 2019 | 498 | 0.090 |
Why?
|
| Azabicyclo Compounds | 1 | 2010 | 4 | 0.090 |
Why?
|
| Pain Measurement | 6 | 2014 | 468 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2023 | 403 | 0.090 |
Why?
|
| Touch | 2 | 2021 | 12 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2011 | 135 | 0.090 |
Why?
|
| Xerostomia | 2 | 2011 | 7 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 20 | 0.090 |
Why?
|
| Anisotropy | 3 | 2019 | 60 | 0.090 |
Why?
|
| Point Mutation | 1 | 2010 | 29 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 39 | 0.090 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 58 | 0.090 |
Why?
|
| Austria | 2 | 2019 | 6 | 0.090 |
Why?
|
| Germany | 2 | 2019 | 10 | 0.090 |
Why?
|
| Piperazines | 1 | 2010 | 93 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2006 | 58 | 0.080 |
Why?
|
| Teaching | 2 | 2001 | 63 | 0.080 |
Why?
|
| Antibodies, Bacterial | 1 | 2008 | 22 | 0.080 |
Why?
|
| Spasm | 2 | 2022 | 7 | 0.080 |
Why?
|
| Nerve Degeneration | 1 | 2009 | 55 | 0.080 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 4 | 0.080 |
Why?
|
| Psychomotor Agitation | 2 | 2020 | 14 | 0.080 |
Why?
|
| Nausea | 2 | 2005 | 28 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2006 | 161 | 0.080 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2007 | 7 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2009 | 149 | 0.080 |
Why?
|
| Disability Evaluation | 5 | 2011 | 328 | 0.070 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 3 | 2012 | 10 | 0.070 |
Why?
|
| Risk | 2 | 2010 | 216 | 0.070 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 64 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 247 | 0.070 |
Why?
|
| Recurrence | 1 | 2007 | 353 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2008 | 142 | 0.070 |
Why?
|
| Wrist | 1 | 2006 | 17 | 0.070 |
Why?
|
| Time | 1 | 2005 | 17 | 0.070 |
Why?
|
| Somatoform Disorders | 1 | 2005 | 20 | 0.070 |
Why?
|
| Gait | 2 | 2023 | 406 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2006 | 131 | 0.060 |
Why?
|
| Constipation | 1 | 2005 | 22 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2005 | 66 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2007 | 117 | 0.060 |
Why?
|
| Dizziness | 1 | 2005 | 20 | 0.060 |
Why?
|
| Catechols | 1 | 2005 | 1 | 0.060 |
Why?
|
| Nitrophenols | 1 | 2005 | 4 | 0.060 |
Why?
|
| Ergolines | 1 | 2005 | 14 | 0.060 |
Why?
|
| Nitriles | 1 | 2005 | 13 | 0.060 |
Why?
|
| Placebos | 1 | 2005 | 82 | 0.060 |
Why?
|
| Benzophenones | 1 | 2005 | 27 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 286 | 0.060 |
Why?
|
| Family | 1 | 2006 | 95 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 410 | 0.060 |
Why?
|
| Mass Screening | 1 | 2006 | 180 | 0.060 |
Why?
|
| Reference Values | 4 | 2008 | 232 | 0.060 |
Why?
|
| Sickness Impact Profile | 3 | 2008 | 19 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2005 | 95 | 0.060 |
Why?
|
| Mental Status Schedule | 2 | 2015 | 114 | 0.060 |
Why?
|
| Social Skills | 1 | 2023 | 15 | 0.060 |
Why?
|
| Disease Progression | 3 | 2014 | 812 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 401 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 142 | 0.060 |
Why?
|
| International Classification of Diseases | 1 | 2023 | 23 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2009 | 957 | 0.050 |
Why?
|
| Employment | 1 | 2023 | 42 | 0.050 |
Why?
|
| Reaction Time | 1 | 2003 | 124 | 0.050 |
Why?
|
| Cognitive Dysfunction | 1 | 2012 | 969 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2022 | 53 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 109 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 49 | 0.050 |
Why?
|
| Water | 1 | 2022 | 33 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 494 | 0.050 |
Why?
|
| Caregivers | 2 | 2008 | 144 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 26 | 0.050 |
Why?
|
| Blinking | 1 | 2021 | 3 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 39 | 0.050 |
Why?
|
| Acetamides | 1 | 2001 | 7 | 0.050 |
Why?
|
| Pantothenic Acid | 1 | 2020 | 1 | 0.050 |
Why?
|
| Family Health | 2 | 2010 | 38 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2010 | 74 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2013 | 75 | 0.040 |
Why?
|
| Olfaction Disorders | 2 | 2012 | 53 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2010 | 299 | 0.040 |
Why?
|
| Adrenal Medulla | 2 | 1990 | 31 | 0.040 |
Why?
|
| Risk Factors | 3 | 2011 | 2466 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2009 | 22 | 0.040 |
Why?
|
| Research Subjects | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sample Size | 1 | 2018 | 25 | 0.040 |
Why?
|
| Neurosurgery | 2 | 1990 | 50 | 0.040 |
Why?
|
| Child | 1 | 2023 | 1379 | 0.040 |
Why?
|
| Back | 1 | 1998 | 3 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2010 | 199 | 0.040 |
Why?
|
| Head Movements | 1 | 1998 | 7 | 0.040 |
Why?
|
| Muscle Relaxants, Central | 1 | 1997 | 5 | 0.040 |
Why?
|
| Baclofen | 1 | 1997 | 15 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 79 | 0.040 |
Why?
|
| Self Report | 1 | 2018 | 221 | 0.040 |
Why?
|
| Diabetes Insipidus | 1 | 1977 | 3 | 0.040 |
Why?
|
| Vasopressins | 1 | 1977 | 6 | 0.040 |
Why?
|
| Cat Diseases | 1 | 1977 | 5 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 761 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 351 | 0.040 |
Why?
|
| Wrist Joint | 2 | 2008 | 61 | 0.040 |
Why?
|
| Accelerometry | 1 | 2017 | 87 | 0.040 |
Why?
|
| Comorbidity | 1 | 2018 | 504 | 0.030 |
Why?
|
| Motor Skills | 2 | 2009 | 62 | 0.030 |
Why?
|
| Arm | 2 | 2008 | 78 | 0.030 |
Why?
|
| Muscle Relaxation | 2 | 2006 | 5 | 0.030 |
Why?
|
| Elbow Joint | 2 | 2008 | 131 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2017 | 117 | 0.030 |
Why?
|
| Neurophysiology | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2015 | 6 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2015 | 12 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 18 | 0.030 |
Why?
|
| Functional Neuroimaging | 1 | 2014 | 9 | 0.030 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1994 | 4 | 0.030 |
Why?
|
| Respiration | 1 | 2015 | 35 | 0.030 |
Why?
|
| Cerebrum | 1 | 2014 | 10 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 2005 | 0.030 |
Why?
|
| Atrophy | 1 | 2014 | 106 | 0.030 |
Why?
|
| Observation | 1 | 2014 | 16 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2009 | 165 | 0.030 |
Why?
|
| Bromocriptine | 1 | 1993 | 15 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 148 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 90 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 258 | 0.030 |
Why?
|
| Muscles | 1 | 1993 | 73 | 0.030 |
Why?
|
| Dementia | 2 | 2012 | 527 | 0.030 |
Why?
|
| Extremities | 1 | 2012 | 33 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2013 | 94 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2013 | 84 | 0.030 |
Why?
|
| beta-Glucosidase | 1 | 2012 | 1 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 2012 | 11 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 1992 | 53 | 0.030 |
Why?
|
| Injections | 1 | 1992 | 59 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2011 | 4 | 0.030 |
Why?
|
| Blepharoptosis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 153 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 56 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 131 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 1990 | 14 | 0.020 |
Why?
|
| Neuromuscular Diseases | 1 | 1990 | 10 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 4 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2012 | 192 | 0.020 |
Why?
|
| Eszopiclone | 1 | 2010 | 4 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 50 | 0.020 |
Why?
|
| Memory Disorders | 1 | 2012 | 177 | 0.020 |
Why?
|
| Thalamus | 1 | 2010 | 28 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 37 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 86 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 216 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 124 | 0.020 |
Why?
|
| Attention | 1 | 2010 | 145 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2009 | 110 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 1990 | 113 | 0.020 |
Why?
|
| Dysarthria | 1 | 2009 | 5 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2009 | 23 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2009 | 28 | 0.020 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2009 | 10 | 0.020 |
Why?
|
| Diffusion | 1 | 2009 | 28 | 0.020 |
Why?
|
| Microelectrodes | 1 | 2009 | 36 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2009 | 66 | 0.020 |
Why?
|
| Memory | 1 | 2010 | 323 | 0.020 |
Why?
|
| Biological Assay | 1 | 2008 | 9 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2008 | 10 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2008 | 54 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2008 | 19 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2008 | 12 | 0.020 |
Why?
|
| Dopamine | 1 | 2009 | 161 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2008 | 55 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2008 | 70 | 0.020 |
Why?
|
| Action Potentials | 1 | 2008 | 136 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 533 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 214 | 0.020 |
Why?
|
| Handwriting | 1 | 2006 | 2 | 0.020 |
Why?
|
| Motor Cortex | 1 | 2006 | 18 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 98 | 0.020 |
Why?
|
| Torque | 1 | 2006 | 29 | 0.020 |
Why?
|
| Weights and Measures | 1 | 2005 | 8 | 0.020 |
Why?
|
| Neurons | 1 | 2009 | 381 | 0.020 |
Why?
|
| Demography | 1 | 2005 | 78 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 56 | 0.020 |
Why?
|
| Antibody Formation | 1 | 2005 | 39 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2005 | 51 | 0.020 |
Why?
|
| Cues | 1 | 2005 | 61 | 0.020 |
Why?
|
| Cognition | 1 | 2013 | 1314 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 197 | 0.010 |
Why?
|
| Mice | 1 | 2008 | 1625 | 0.010 |
Why?
|
| Clozapine | 1 | 2003 | 10 | 0.010 |
Why?
|
| Nursing Homes | 1 | 2003 | 38 | 0.010 |
Why?
|
| Anorexia | 1 | 2003 | 4 | 0.010 |
Why?
|
| Paresthesia | 1 | 2003 | 6 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2003 | 13 | 0.010 |
Why?
|
| Primidone | 1 | 2003 | 1 | 0.010 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 5 | 0.010 |
Why?
|
| Vomiting | 1 | 2003 | 18 | 0.010 |
Why?
|
| Hyponatremia | 1 | 2003 | 10 | 0.010 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2003 | 33 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 47 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 2003 | 47 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 101 | 0.010 |
Why?
|
| Elbow | 1 | 2001 | 42 | 0.010 |
Why?
|
| Receptors, Glutamate | 1 | 2001 | 5 | 0.010 |
Why?
|
| Retreatment | 1 | 1999 | 14 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2003 | 685 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 310 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1998 | 21 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 40 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 1997 | 13 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 1997 | 26 | 0.010 |
Why?
|
| Chlorpropamide | 1 | 1977 | 1 | 0.010 |
Why?
|
| Thirst | 1 | 1977 | 2 | 0.010 |
Why?
|
| Polyuria | 1 | 1977 | 2 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1977 | 9 | 0.010 |
Why?
|
| Cats | 1 | 1977 | 75 | 0.010 |
Why?
|
| Dogs | 1 | 1977 | 261 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 197 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1993 | 352 | 0.010 |
Why?
|